Tag: Generics

This article is part of a Chronicle. See more from this Chronicle Ankur Kapoor, Rosa Morales, Apr 29, 2014 Nearly a year after the Supreme Court...

This article is part of a Chronicle. See more from this Chronicle Donald Falk, Christopher Kelly, Apr 29, 2014 As with patent infringement litigation in many...

Fiona Scott Morton, Dec 20, 2013 This article lays out the economics of competition between branded and generic pharmaceuticals and its welfare consequences. I explain...

Pierre Regibeau, Dec 20, 2013 Antitrust concerns about “pay-for-delay” patent settlements are based on two theories of harms, one that stresses the need for courts...

James Langenfeld, Dec 30, 2013 Patent settlement agreements that involve payments from brand-name drug manufacturers to generic drug manufacturers (so called "reverse payments" or "pay...

Daniela Ampollini, Jul 15, 2013 It is obvious to all that know even a little of patent law, that the validity (and, even before, the...

Patrick Harrison, Kristina Nordlander, Jul 27, 2012 In June 2005, the European Commission issued a decision finding that AstraZeneca had breached Article 102 TFEUby engaging...

Stefano Grassani, Jul 27, 2012 On Jan. 11, 2012, the Italian Antitrust Authority ("IAA") found Pfizer Inc. and its Swedish and Italian subsidiaries guilty of...

Daniela Ampollini, Jul 27, 2012 The January 2012 decision of the Italian Antitrust Authority ("IAA") in the Pfizer case, involving Pfizer's actions to counter the marketing...

Sean-Paul Brankin, Jul 27, 2012 On July 6, 2011, the European Commission closed the case file in itsBoehringer/Almirall investigation. It did so without a formal...